全球人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI) 市场 – 行业趋势和 2029 年预测

市场分析和规模

在人类免疫缺陷病毒 1 型 (HIV-1) 感染的一线治疗中，目前建议使用整合酶链转移抑制剂 (INSTIs)。第一代 INSTIs 是成功的，但它们有可能选择病毒抗性。最近开发了几种有效的第二代 INSTIs，它们对野生型 (WT) HIV-1 整合酶和几种第一代 INSTI 抗性突变均有效。由于对这些新的第二代 INSTIs 的耐药性可以忽略不计，因此已经开发了其他针对 HIV-1 患者的治疗技术。由于 INSTIs 具有高抗病毒效力，并且在某些情况下具有生物利用度特征 (PrEP)，因此它们也可能在暴露前预防中发挥关键作用。

Data Bridge Market Research 分析，人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI) 市场在 2021 年的价值为 7.615 亿美元，预计到 2029 年将达到 12.3216 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 6.20%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Integrase strand transfer inhibitors stop integrase, a human immunodeficiency virus Type 1 (HIV-1) viral enzyme involved in integrating viral DNA into the host chromosome, from working. For viral replication to take place, the viral DNA must be integrated into the host DNA. Integrase strand transfer inhibitors are used to prevent the human immunodeficiency virus from reproducing in the host and are not a cure for HIV or AIDS.

Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Dynamics

Drivers

• Increasing prevalence of human immunodeficiency virus (HIV)

The rising prevalence of human immunodeficiency virus (HIV) is anticipated to influence the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market's growth. Bictegravir (BIC), elvitegravir (EVG), dolutegravir (DTG) and raltegravir (RAL) are four integrase strand transfer inhibitors (INSTIs) that have been licensed for use in antiretroviral therapy (ART)-naive HIV patients. Cabotegravir (CAB) is a novel INSTI that has been authorized for use in combination with rilpivirine (RPV) in a long-acting injectable comprehensive antiretroviral (ARV) regimen to replace a stable oral regimen in patients with viral suppression.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market. Additionally, side effects of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI) market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI) market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.

Global Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Scope

The human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Elvitegravir
• Cabotegravir
• Raltegravir
• Dolutegravir
• Other

Application

• HIV Infection
• Occupational Exposure
• Pre-Exposure Prophylaxis

Dosage

• Injection
• Tablet
• Others

Route of Administration

• Oral
• Intramuscular
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Regional Analysis/Insights

对人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI) 市场进行了分析，并按国家、药物、应用、剂量、给药途径、最终用户和分销渠道提供了市场规模见解和趋势，如上所述。

人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI)？市场报告涵盖的国家包括北美的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区（作为中东和非洲 (MEA) 的一部分）、巴西、阿根廷和南美洲其他地区（作为南美洲的一部分）

由于人类免疫缺陷病毒 1 型在北美的流行率不断上升，北美在人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI) 市场中占据主导地位。此外，主要关键参与者的不断增加和完善的医疗保健基础设施将进一步推动该地区市场的增长率。

由于医疗保健支出的增加和医疗保健基础设施的改善，预计亚太地区在 2022-2029 年预测期内将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。    

竞争格局和人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI) 市场份额分析

人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI)? 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI)? 市场的关注有关。

人类免疫缺陷病毒 (HIV) 整合酶链转移抑制剂 (INSTI) 市场的一些主要参与者包括：

• 吉利德科学公司（美国）
• Emcure Pharmaceuticals Limited.（印度）
• Cipla Inc.（美国）
• 异性恋（印度）
• Bausch Health Companies Inc.（加拿大）
• 强生私人有限公司（美国）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• Biocon（印度）
• 百时美施贵宝公司 (美国)
• 葛兰素史克公司 (英国)
• 上海迪赛诺制药有限公司 (中国)
• Laurus Labs（印度）
• Ipca Laboratories Ltd.（印度）
• Flamingo Pharma Limited（印度）   

SKU-68495